Technical Analysis for MREO - Mereo BioPharma Group plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gapped Down | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.83% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 4.31% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 4.31% | |
| NR7 | Range Contraction | 4.31% | |
| Stochastic Reached Oversold | Weakness | 4.31% | |
| Inside Day | Range Contraction | 4.31% | |
| Wide Bands | Range Expansion | 4.31% | |
| Down 3 Days in a Row | Weakness | 4.31% | |
| Down 4 Days in a Row | Weakness | 4.31% |
| Alert | Time |
|---|---|
| Possible NR7 | about 6 hours ago |
| Possible Inside Day | about 6 hours ago |
| Gap Down Closed | about 8 hours ago |
| Gap Down Partially Closed | about 10 hours ago |
| Gapped Down (Partial) | about 10 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/21/2024
Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo's strategy is to selectively acquire product candidates that have substantial preclinical, clinical and manufacturing data packages. Mereo's four product candidates have previously generated positive clinical data for Mereo's target indications or in related indications. Mereo has commenced randomized Phase 2 clinical trials for all four of the product candidates. In connection with the merger with OncoMed, Mereo added two candidates to its pipeline, Navicixizumab and Etigilimab.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Drug Discovery Rare Diseases Clinical Research Clinical Trial Compugen
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Drug Discovery Rare Diseases Clinical Research Clinical Trial Compugen
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.5 |
| 52 Week Low | 1.07 |
| Average Volume | 1,142,814 |
| 200-Day Moving Average | 2.76 |
| 50-Day Moving Average | 3.31 |
| 20-Day Moving Average | 3.69 |
| 10-Day Moving Average | 3.76 |
| Average True Range | 0.28 |
| RSI (14) | 51.92 |
| ADX | 30.9 |
| +DI | 22.94 |
| -DI | 18.42 |
| Chandelier Exit (Long, 3 ATRs) | 3.67 |
| Chandelier Exit (Short, 3 ATRs) | 4.09 |
| Upper Bollinger Bands | 4.24 |
| Lower Bollinger Band | 3.14 |
| Percent B (%b) | 0.45 |
| BandWidth | 29.90 |
| MACD Line | 0.08 |
| MACD Signal Line | 0.14 |
| MACD Histogram | -0.0571 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.93 | ||||
| Resistance 3 (R3) | 3.91 | 3.78 | 3.88 | ||
| Resistance 2 (R2) | 3.78 | 3.71 | 3.80 | 3.86 | |
| Resistance 1 (R1) | 3.71 | 3.66 | 3.75 | 3.73 | 3.85 |
| Pivot Point | 3.58 | 3.58 | 3.60 | 3.60 | 3.58 |
| Support 1 (S1) | 3.51 | 3.51 | 3.55 | 3.53 | 3.41 |
| Support 2 (S2) | 3.38 | 3.46 | 3.40 | 3.40 | |
| Support 3 (S3) | 3.31 | 3.38 | 3.38 | ||
| Support 4 (S4) | 3.33 |
